CanniMed begins shipping topical cream kits to patients
2018-02-28 08:06 ET - News Release
Ms. Dara Willis reports
CANNIMED MEDICAL CANNABIS TOPICAL CREAM PROVIDES FAST-ACTING RELIEF TO PATIENTS IN NEED
CanniMed Therapeutics Inc. has started fulfilling orders and shipping CanniMed topical cream kits to registered patients. This innovative new product is a fusion of CanniMed's industry-leading medical cannabis oil with Kalaya{A ™} Carrier Base Gel, created by Avaria Health & Beauty Corp. ("Avaria"), one of Canada's leading experts in the creation of advanced topical creams, gels, lotions and salves.
The CanniMed Topical Cream Kit includes one bottle of CanniMed's industry-leading medical cannabis oil and one jar of Kalaya Carrier Base Gel that are mixed together by the patient to create an innovative medical cannabis topical cream. (Graphic: Business Wire)
"Patients and physicians have been demanding a high-quality medical cannabis topical cream and we are pleased to be able to offer one of Canada's most robust and innovative carrier gels to blend with our standardized and trusted oils," said Brent Zettl, President and CEO of CanniMed. "This is a whole new form of delivery for medical cannabis, ideal for patients who do not wish ingest or vaporize and prefer only localized treatment for their condition."
Benefits of CanniMed Topical Cream
Localized treatment: a concentrated dose of the medicinal ingredients is delivered to the affected area only
Fast-acting: the unique formulation of CanniMedtrademark Topical Cream optimizes absorption by the skin, allowing for more medicinal ingredients to reach the affected area quickly
Convenient: CanniMedtrademark Topical Cream is shelf stable (does not require refrigeration) making it ideal to use at any time
"Our Medical Formulating Team has created a one-of-a-kind product designed to provide an effective, alternative route of administration for patients looking for a different way to use medical cannabis," said Dr. Keith Burk, CEO of Avaria Health & Beauty. "We look forward to seeing the difference that this unique option has on the wellbeing of patients, along with other exciting products in development with CanniMed Therapeutics Inc."
There is a considerable amount of anecdotal evidence supporting the topical application of medical cannabis, and a growing body of scientific evidence respecting topical application for conditions such as inflammation, neuropathic pain (particularly in patients with Multiple Sclerosis)1 and allergic skin conditions2. A recent study indicates that CB2 receptors may be key in treating the symptoms of rheumatoid arthritis3. CanniMedtrademark Topical Cream is suggested to provide relief by binding to a patient's CB2 receptors.
CanniMedtrademark Topical Cream is now available and delivered as a kit containing:
One bottle of CanniMedtrademark Oil 1:20 or CanniMedtrademark Oil 10:10,
One jar of Kalaya{A ™} Carrier Base Gel, and
One spatula for mixing.
Patients mix the CanniMed Oil and Carrier Base Gel together in the comfort of their own home. Once mixed, the clear gel transforms into a luxurious white topical cream similar in cosmetic elegance to those found at luxury cosmetics counters.
CanniMedtrademark Topical Cream retails for $189.99 (60 mL CanniMedtrademark Oil 10:10 + 120 mL Kalaya{A ™} Carrier Base Gel) and $143.99 (60 mL CanniMedtrademark Oil 1:20 + 120 mL Kalaya{A ™} Carrier Base Gel).
About CanniMed Therapeutics Inc.
CanniMed is a Canadian-based, international plant biopharmaceutical company and a leader in the Canadian medical cannabis industry, with 17 years of pharmaceutical cannabis cultivation experience, state-of-the-art, GMP-compliant production process and world class research and development platforms with a wide range of pharmaceutical-grade cannabis products. In addition, the Company has an active plant biotechnology research and product development program focused on the production of plant-based materials for pharmaceutical, agricultural and environmental applications.
1 Jorge LL, Feres CC, Teles VE. Topical preparations for pain relief: efficacy and patient adherence. Journal of Pain Research. 2011;4:11-24. doi:10.2147/JPR.S9492.
2 Gaffal E, Cron M, Glodde N, Tuting T. Anti-inflammatory activity of topical THC in DNFB-mediated mouse allergic contact dermatitis independent of CB1 and CB2 receptors. Allergy 2013; 68: 994{A –}1000.